Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 2Gastrointestinal 1Dermatologic 1

Conditions

Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Adenocarcinoma 1

Interventions

Oxaliplatin 300Fluorouracil 273Bevacizumab 238Gemcitabine 236Leucovorin 213Capecitabine 207pembrolizumab 202Irinotecan 159Nivolumab 158Cisplatin 150Specimen Handling 144Magnetic Resonance Spectroscopy 130130-nm albumin-bound paclitaxel 119Paclitaxel 109durvalumab 107Cetuximab 104Radiotherapy 99atezolizumab 94Drug Therapy 94Biopsy 93tislelizumab 81Albumin-Bound Paclitaxel 81Taxes 74Folfox protocol 68lenvatinib 67Carboplatin 66regorafenib 60Blood Specimen Collection 60sintilimab 54Ipilimumab 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
1-methyltryptophan × Gastrointestinal × 1 year × Clear all
NCT02077881 2026-04-03

Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer

Lumos Pharma

Phase 1/2 Completed
157 enrolled 18 charts
Gastrointestinal

Adenocarcinoma, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡